JP2015527387A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015527387A5 JP2015527387A5 JP2015530495A JP2015530495A JP2015527387A5 JP 2015527387 A5 JP2015527387 A5 JP 2015527387A5 JP 2015530495 A JP2015530495 A JP 2015530495A JP 2015530495 A JP2015530495 A JP 2015530495A JP 2015527387 A5 JP2015527387 A5 JP 2015527387A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- heterocyclyl
- heteroaryl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 255
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 79
- 125000000623 heterocyclic group Chemical group 0.000 claims description 55
- 125000003545 alkoxy group Chemical group 0.000 claims description 53
- 125000001072 heteroaryl group Chemical group 0.000 claims description 53
- 229910052739 hydrogen Inorganic materials 0.000 claims description 49
- 239000001257 hydrogen Substances 0.000 claims description 49
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 44
- 125000001424 substituent group Chemical group 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 34
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 34
- 125000001153 fluoro group Chemical group F* 0.000 claims description 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 25
- -1 trifluoromethoxy, cyano, nitro, hydroxy, amino, carboxy, carbamoyl Chemical group 0.000 claims description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 18
- 125000005843 halogen group Chemical group 0.000 claims description 18
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 17
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 17
- 125000001589 carboacyl group Chemical group 0.000 claims description 9
- 125000005647 linker group Chemical group 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000012453 solvate Substances 0.000 claims description 7
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 6
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 5
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 125000004043 oxo group Chemical group O=* 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 4
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 3
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1216017.2 | 2012-09-07 | ||
| GBGB1216017.2A GB201216017D0 (en) | 2012-09-07 | 2012-09-07 | Inhibitor compounds |
| PCT/GB2013/052360 WO2014037750A1 (en) | 2012-09-07 | 2013-09-09 | Inhibitor compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017182377A Division JP6496376B2 (ja) | 2012-09-07 | 2017-09-22 | 阻害剤化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015527387A JP2015527387A (ja) | 2015-09-17 |
| JP2015527387A5 true JP2015527387A5 (OSRAM) | 2017-09-07 |
| JP6216791B2 JP6216791B2 (ja) | 2017-10-18 |
Family
ID=47137117
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015530495A Active JP6216791B2 (ja) | 2012-09-07 | 2013-09-09 | 阻害剤化合物 |
| JP2017182377A Expired - Fee Related JP6496376B2 (ja) | 2012-09-07 | 2017-09-22 | 阻害剤化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017182377A Expired - Fee Related JP6496376B2 (ja) | 2012-09-07 | 2017-09-22 | 阻害剤化合物 |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US9409907B2 (OSRAM) |
| EP (2) | EP3293183B1 (OSRAM) |
| JP (2) | JP6216791B2 (OSRAM) |
| CN (1) | CN104837829B (OSRAM) |
| AU (2) | AU2013311434B2 (OSRAM) |
| BR (1) | BR112015004489B1 (OSRAM) |
| CA (1) | CA2884006C (OSRAM) |
| CY (1) | CY1119714T1 (OSRAM) |
| DK (2) | DK3293183T3 (OSRAM) |
| ES (2) | ES2655194T3 (OSRAM) |
| GB (1) | GB201216017D0 (OSRAM) |
| HR (1) | HRP20171835T1 (OSRAM) |
| HU (1) | HUE036259T2 (OSRAM) |
| LT (1) | LT2892889T (OSRAM) |
| NO (1) | NO2892889T3 (OSRAM) |
| PL (1) | PL2892889T3 (OSRAM) |
| PT (1) | PT2892889T (OSRAM) |
| RS (1) | RS56750B1 (OSRAM) |
| RU (1) | RU2673079C2 (OSRAM) |
| SI (1) | SI2892889T1 (OSRAM) |
| SM (1) | SMT201700596T1 (OSRAM) |
| WO (1) | WO2014037750A1 (OSRAM) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9017724B2 (en) | 2004-02-24 | 2015-04-28 | The General Hospital Corporation | Catalytic radiofluorination |
| JP5501339B2 (ja) | 2008-03-21 | 2014-05-21 | ザ ジェネラル ホスピタル コーポレイション | アルツハイマー病及び関連疾患の検出及び治療のための化合物及び組成物 |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| PH12019500143B1 (en) | 2013-08-23 | 2023-03-24 | Neupharma Inc | Certain chemical entities, compositions, and methods |
| GB201403536D0 (en) * | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| JP6616934B2 (ja) * | 2014-05-22 | 2019-12-04 | 株式会社 資生堂 | レナリドミドの光学分割方法 |
| AU2016220219B2 (en) * | 2015-02-17 | 2020-05-14 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| JP6993233B2 (ja) | 2015-04-17 | 2022-01-13 | ネザーランズ トランスレーショナル リサーチ センター ビー．ブイ． | Ｔｔｋ阻害剤化学療法の為の予後バイオマーカー |
| LT3305785T (lt) * | 2015-05-29 | 2021-11-10 | Teijin Pharma Limited | Pirido[3,4-d]pirimidino dariniai ir jų farmaciniu požiūriu priimtinos druskos |
| KR102591886B1 (ko) | 2015-07-21 | 2023-10-20 | 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. | 축합고리 피리미딘계 화합물, 중간체, 이의 제조 방법, 조성물 및 응용 |
| GB201522532D0 (en) * | 2015-12-21 | 2016-02-03 | Cancer Rec Tech Ltd | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives |
| WO2018035061A1 (en) | 2016-08-15 | 2018-02-22 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| TWI799399B (zh) | 2016-11-28 | 2023-04-21 | 日商帝人製藥股份有限公司 | 吡啶并〔３，４－ｄ〕嘧啶衍生物及其藥學上所容許之鹽 |
| NZ752990A (en) | 2016-11-28 | 2025-08-29 | Teijin Pharma Ltd | Crystal of pyrido[3, 4-d]pyrimidine derivative or solvate thereof |
| CA3067773A1 (en) * | 2017-06-20 | 2018-12-27 | The Institute Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
| GB201709840D0 (en) * | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
| US11175469B2 (en) | 2017-10-26 | 2021-11-16 | CommScope Connectivity Belgium BVBA | Telecommunications system |
| GB201809460D0 (en) * | 2018-06-08 | 2018-07-25 | Crt Pioneer Fund Lp | Salt form |
| GB201809458D0 (en) * | 2018-06-08 | 2018-07-25 | Crt Pioneer Fund Lp | Salt form |
| LT4053118T (lt) | 2019-10-30 | 2024-12-10 | Genfleet Therapeutics (Shanghai) Inc. | Pakeistas heterociklinis junginys su sujungtais žiedais, jo paruošimo būdas ir naudojimas farmacijoje |
| WO2021146370A1 (en) * | 2020-01-15 | 2021-07-22 | Blueprint Medicines Corporation | Map4k1 inhibitors |
| KR102396930B1 (ko) * | 2020-01-15 | 2022-05-12 | 한국과학기술연구원 | 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 |
| TW202202498A (zh) * | 2020-07-01 | 2022-01-16 | 大陸商四川海思科製藥有限公司 | 一種並環雜環衍生物及其在醫藥上的應用 |
| WO2022015423A1 (en) * | 2020-07-16 | 2022-01-20 | Dermavant Sciences GmbH | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE |
| US20230303564A1 (en) * | 2020-08-17 | 2023-09-28 | Medshine Discovery Inc. | Pyrimidine ring compound |
| EP4247795A1 (en) | 2020-11-18 | 2023-09-27 | Deciphera Pharmaceuticals, LLC | Gcn2 and perk kinase inhibitors and methods of use thereof |
| CN115583946A (zh) * | 2021-07-06 | 2023-01-10 | 赛诺哈勃药业（成都）有限公司 | 杂环化合物及其作为cdk抑制剂的用途 |
| MX2024006975A (es) * | 2021-12-16 | 2024-08-27 | Transthera Sciences Nanjing Inc | Inhibidor de cdk9 y uso del mismo. |
| TW202509031A (zh) * | 2023-05-15 | 2025-03-01 | 美商阿列克希雅醫療公司 | Ｃｄｋ抑制劑萘啶化合物 |
| WO2025038785A1 (en) * | 2023-08-16 | 2025-02-20 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions, and therapeutic applications |
| CN117800875B (zh) * | 2023-12-21 | 2024-10-22 | 泰州精英化成医药科技有限公司 | 一种反式-(N-Boc-4-氨基环己基)乙酸的制备方法 |
| WO2025155740A1 (en) * | 2024-01-17 | 2025-07-24 | Iambic Therapeutics, Inc. | Combinations comprising aza-quinazoline compounds for use in the treatment of cancer |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2697710A (en) | 1953-01-02 | 1954-12-21 | Burroughs Wellcome Co | Pyrido (2,3-d) pyrimidines and method of preparing same |
| US3021332A (en) | 1954-01-04 | 1962-02-13 | Burroughs Wellcome Co | Pyrido (2, 3-d) pyrimidine compounds and method of making |
| ES2146782T3 (es) | 1994-11-14 | 2000-08-16 | Warner Lambert Co | 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa. |
| US7053070B2 (en) | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
| AR030044A1 (es) | 2000-01-25 | 2003-08-13 | Warner Lambert Co | Pirido (2,3-d ) pirimidin-2,7-diaminas inhibidores de quinasas |
| AU6118001A (en) | 2000-05-03 | 2001-11-12 | Tularik Inc | Combination therapeutic compositions and methods of use |
| WO2002090360A1 (en) | 2001-05-10 | 2002-11-14 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| WO2003000011A2 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel pyridopyrimidines and uses thereof |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| CA2470214A1 (en) | 2001-12-13 | 2003-06-26 | Abbott Laboratories | 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer |
| MXPA04008592A (es) | 2002-03-07 | 2004-12-06 | Hoffmann La Roche | Inhibidores de piridina biciclica y pirimidina p38 cinasa. |
| JP4252534B2 (ja) * | 2002-08-06 | 2009-04-08 | エフ．ホフマン−ラ ロシュ アーゲー | ｐ−３８ＭＡＰキナーゼインヒビターとしての６−アルコキシ−ピリド−ピリミジン類 |
| US20040092521A1 (en) | 2002-11-12 | 2004-05-13 | Altenbach Robert J. | Bicyclic-substituted amines as histamine-3 receptor ligands |
| WO2004043458A1 (en) | 2002-11-12 | 2004-05-27 | Abbott Laboratories | Bicyclic-substituted amines as histamine-3 receptor ligands |
| JP2006516561A (ja) | 2003-01-17 | 2006-07-06 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類 |
| US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| US20050256118A1 (en) | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| MX2008000017A (es) | 2005-06-28 | 2008-03-26 | Sanofi Aventis | Derivados de isoquinolina como inhibidores de rho-cinasa. |
| NZ569817A (en) * | 2005-12-21 | 2011-10-28 | Abbott Lab | Anti-viral compounds |
| TW200808739A (en) * | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
| JP2009535393A (ja) | 2006-05-01 | 2009-10-01 | ファイザー・プロダクツ・インク | 置換２−アミノ縮合複素環式化合物 |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| KR20090092287A (ko) * | 2006-12-22 | 2009-08-31 | 노파르티스 아게 | Ｐｄｋ１ 억제를 위한 퀴나졸린 |
| WO2008135232A1 (en) | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
| AU2008296479A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
| WO2009084695A1 (ja) * | 2007-12-28 | 2009-07-09 | Carna Biosciences Inc. | ２－アミノキナゾリン誘導体 |
| GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB0812969D0 (en) | 2008-07-15 | 2008-08-20 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| EP2427195B1 (en) | 2009-05-07 | 2019-05-01 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| WO2011109059A1 (en) | 2010-03-01 | 2011-09-09 | Gtx, Inc. | Compounds for treatment of cancer |
| GB201011182D0 (en) | 2010-07-02 | 2010-08-18 | Wireless Fibre Systems Ltd | Riser wireless communications system |
| US9333205B2 (en) * | 2010-07-30 | 2016-05-10 | Nerviano Medical Sciences S.R.L. | Isoxazolo-quinazolines as modulators of protein kinase activity |
| ES2377610B1 (es) | 2010-09-01 | 2013-02-05 | Institut Químic de Sarriá CETS Fundació Privada | Preparación de compuestos pirido[2,3-d]pirimidin-7(8h)-ona sustituidos. |
| JP2013540145A (ja) | 2010-10-21 | 2013-10-31 | ウニベルシテート デス ザールランデス | コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤 |
| WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| JP6026427B2 (ja) | 2010-12-17 | 2016-11-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 置換６，６−縮合窒素複素環化合物及びその使用 |
| EP2655334B1 (en) | 2010-12-22 | 2018-10-03 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| TWI450891B (zh) | 2010-12-29 | 2014-09-01 | Dev Center Biotechnology | 新穎微管蛋白抑制劑 |
| RU2591191C2 (ru) * | 2011-01-26 | 2016-07-10 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Трициклические пирроло производные, способ их получения и их применение в качестве ингибиторов киназы |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| US9745191B2 (en) | 2011-04-11 | 2017-08-29 | Saudi Arabian Oil Company | Auto thermal reforming (ATR) catalytic structures |
| CN103997894B (zh) | 2011-07-29 | 2016-08-24 | 麦迪韦逊前列腺治疗股份有限公司 | 乳癌的治疗 |
| WO2013053051A1 (en) | 2011-10-12 | 2013-04-18 | University Health Network | Indazole compounds as kinase inhibitors and method of treating cancer with same |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| GB201216017D0 (en) * | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| WO2014134169A1 (en) | 2013-02-26 | 2014-09-04 | Senex Biotechnology, Inc. | Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer |
| CN105916501A (zh) | 2013-12-06 | 2016-08-31 | 豪夫迈·罗氏有限公司 | 用于治疗局部晚期或转移性雌激素受体阳性乳腺癌的雌激素受体调节剂 |
| GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| SG11201607448PA (en) | 2014-03-11 | 2016-10-28 | Queensland Inst Med Res | Determining cancer agressiveness, prognosis and responsiveness to treatment |
| JP2017520603A (ja) | 2014-07-14 | 2017-07-27 | シグナル ファーマシューティカルズ，エルエルシー | 置換ピロロピリミジン化合物を使用するがんの治療方法及びその組成物 |
| WO2016073771A2 (en) | 2014-11-06 | 2016-05-12 | Ohio State Innovation Foundation | Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors |
| GB201522532D0 (en) | 2015-12-21 | 2016-02-03 | Cancer Rec Tech Ltd | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives |
| GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
| CA3067773A1 (en) | 2017-06-20 | 2018-12-27 | The Institute Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
-
2012
- 2012-09-07 GB GBGB1216017.2A patent/GB201216017D0/en not_active Ceased
-
2013
- 2013-09-09 AU AU2013311434A patent/AU2013311434B2/en not_active Ceased
- 2013-09-09 SM SM20170596T patent/SMT201700596T1/it unknown
- 2013-09-09 NO NO13760106A patent/NO2892889T3/no unknown
- 2013-09-09 BR BR112015004489-1A patent/BR112015004489B1/pt not_active IP Right Cessation
- 2013-09-09 RS RS20171314A patent/RS56750B1/sr unknown
- 2013-09-09 DK DK17192253.7T patent/DK3293183T3/da active
- 2013-09-09 SI SI201330829T patent/SI2892889T1/sl unknown
- 2013-09-09 US US14/426,549 patent/US9409907B2/en active Active
- 2013-09-09 JP JP2015530495A patent/JP6216791B2/ja active Active
- 2013-09-09 ES ES13760106.8T patent/ES2655194T3/es active Active
- 2013-09-09 HR HRP20171835TT patent/HRP20171835T1/hr unknown
- 2013-09-09 RU RU2015112580A patent/RU2673079C2/ru active
- 2013-09-09 CA CA2884006A patent/CA2884006C/en active Active
- 2013-09-09 PT PT137601068T patent/PT2892889T/pt unknown
- 2013-09-09 HU HUE13760106A patent/HUE036259T2/hu unknown
- 2013-09-09 EP EP17192253.7A patent/EP3293183B1/en active Active
- 2013-09-09 WO PCT/GB2013/052360 patent/WO2014037750A1/en not_active Ceased
- 2013-09-09 PL PL13760106T patent/PL2892889T3/pl unknown
- 2013-09-09 LT LTEP13760106.8T patent/LT2892889T/lt unknown
- 2013-09-09 EP EP13760106.8A patent/EP2892889B1/en active Active
- 2013-09-09 CN CN201380057967.7A patent/CN104837829B/zh not_active Expired - Fee Related
- 2013-09-09 ES ES17192253T patent/ES2742442T3/es active Active
- 2013-09-09 DK DK13760106.8T patent/DK2892889T3/en active
-
2016
- 2016-04-06 US US15/091,980 patent/US9834552B2/en active Active
- 2016-04-06 US US15/091,887 patent/US9890157B2/en active Active
-
2017
- 2017-09-22 JP JP2017182377A patent/JP6496376B2/ja not_active Expired - Fee Related
- 2017-11-27 AU AU2017268488A patent/AU2017268488B2/en not_active Ceased
- 2017-12-29 CY CY20171101358T patent/CY1119714T1/el unknown
-
2018
- 2018-01-08 US US15/864,499 patent/US10479788B2/en active Active
-
2019
- 2019-10-10 US US16/598,717 patent/US11046688B2/en not_active Expired - Fee Related
-
2021
- 2021-05-13 US US17/319,231 patent/US11897877B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015527387A5 (OSRAM) | ||
| JP2015529217A5 (OSRAM) | ||
| JP2016501191A5 (OSRAM) | ||
| SI2922844T1 (en) | N-PYROLIDINYL, N'-PYRAZOLYL-WATER, TIOUREE, GVANIDINE AND CYANOGVANIDINE COMPOUNDS AS THE BLOOD KINASE INHIBITORS | |
| JP2014504622A5 (OSRAM) | ||
| JP2016537382A5 (OSRAM) | ||
| JP2013537203A5 (OSRAM) | ||
| JP2016529324A5 (OSRAM) | ||
| JP2009515988A5 (OSRAM) | ||
| JP2019514874A5 (OSRAM) | ||
| JP2016506962A5 (OSRAM) | ||
| JP2015143283A5 (OSRAM) | ||
| JP2014500296A5 (OSRAM) | ||
| JP2017509586A5 (OSRAM) | ||
| JP2016506961A5 (OSRAM) | ||
| JP2018536634A5 (OSRAM) | ||
| JP2016516043A5 (OSRAM) | ||
| JP2017508782A5 (OSRAM) | ||
| JP2018516904A5 (OSRAM) | ||
| MY187617A (en) | Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof | |
| JP2016513696A5 (OSRAM) | ||
| RU2021102805A (ru) | 4,6-ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ | |
| JP2015508092A5 (OSRAM) | ||
| JP2016531868A5 (OSRAM) | ||
| JP2020500916A5 (OSRAM) |